Kimia Farma Targets Sales In 2023 To Grow 20.88 Percent To Rp11 Trillion

JAKARTA - PT Kimia Farma (Persero) Tbk (KAEF) targets total sales throughout 2023 of IDR 11 trillion or a growth of 20.88 percent compared to the achievement in 2022 of IDR 9.1 trillion.

The top line projection was conveyed by KAEF Finance Director, Lina Sari during the Public Expose in Jakarta, Wednesday, May 32nd.

"The sales target this year is around Rp. 11 trillion," said Lina.

He revealed, with the increase in net profit, this year KAEF can record a net profit of IDR 130 billion. As is known, last year the company recorded a net loss of IDR 170.05 billion.

In order to achieve the target income statement, according to Lina, this year KAEF has budgeted a capital expenditure (capex) of IDR 1.26 trillion. As of March 31, 2023, he said, the capex funds had been absorbed by IDR 90 billion.

"The capex budget that we have prepared is for the purchase of land and buildings, machinery, vehicles and inventory," said Lina.

He added that the issuance of Mandatory Convert Bonds (OWK) in February 2023 resulted in IDR 315 billion, whose funds were used as operational expenditures, such as purchasing raw materials.

"Until April 2023, we have used this fund of Rp180 billion," said Lina.